Beck Mack & Oliver LLC Has $26.39 Million Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Beck Mack & Oliver LLC lessened its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 2.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,197,490 shares of the company's stock after selling 36,160 shares during the period. Beck Mack & Oliver LLC owned 0.11% of Teva Pharmaceutical Industries worth $26,393,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in TEVA. FMR LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 30.7% in the fourth quarter. FMR LLC now owns 81,983,231 shares of the company's stock valued at $1,806,910,000 after acquiring an additional 19,242,468 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd increased its position in shares of Teva Pharmaceutical Industries by 12.8% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock valued at $859,935,000 after purchasing an additional 4,418,961 shares during the period. Todd Asset Management LLC bought a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter worth $58,243,000. Marshall Wace LLP lifted its holdings in shares of Teva Pharmaceutical Industries by 87.8% in the fourth quarter. Marshall Wace LLP now owns 5,155,402 shares of the company's stock valued at $113,625,000 after buying an additional 2,410,420 shares during the period. Finally, Raymond James Financial Inc. bought a new position in Teva Pharmaceutical Industries during the fourth quarter valued at about $38,914,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have issued reports on TEVA shares. UBS Group dropped their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday, January 30th. Barclays decreased their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, January 30th. StockNews.com lowered shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research note on Monday, April 14th. Piper Sandler lifted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research report on Friday, January 17th. Finally, Bank of America decreased their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $23.43.

Teva Pharmaceutical Industries Stock Down 2.6 %

Shares of NYSE:TEVA traded down $0.35 during trading on Monday, reaching $13.30. 12,058,632 shares of the company traded hands, compared to its average volume of 9,911,347. Teva Pharmaceutical Industries Limited has a 1-year low of $12.47 and a 1-year high of $22.80. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The firm has a market cap of $15.08 billion, a P/E ratio of -9.17, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72. The firm has a fifty day simple moving average of $15.39 and a 200 day simple moving average of $17.65.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.